Similar Items: Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
- Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex)
- Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer
- Modernizing disease assessment in prostate cancer trials: the Prostate Cancer Working Group 4 framework
- Determinants of Adverse Events in Patients with Cancer Who Practiced Self-Medication: A Cross-Sectional Study in Southwestern Uganda
- Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer